Navigation Links
Anodyne Health, Seven Other Companies Join in Significant Expansion of MedAxiom Corporate Partner Program
Date:9/27/2010

JACKSONVILLE, Fla., Sept. 27 /PRNewswire/ -- MedAxiom, a subscription-based service provider and information resource that provides benchmarking and performance data to cardiology practices, today announced a significant expansion to its Corporate Partner program. The company noted that eight additional companies, including Anodyne Health, have joined the program so far this year, providing a wide range of services to its cardiology practice members.  MedAxiom now has more than 30 organizations involved in its Corporate Partner program.

MedAxiom's Corporate Partners include industry leaders such as the American College of Cardiology, Philips Healthcare and more. These partners deliver services that help cardiologists nationwide improve their organizational focus, efficiency and profitability. Those services run the gamut from computer software and hardware services and strategic consultancy to the procurement and delivery of advanced diagnostic tools.

"Cardinal Health is pleased to participate in MedAxiom's Corporate Partner program.  Through our involvement, we have had the opportunity to learn more about the needs of today's busy cardiology practices and better design solutions and services to enhance safety, productivity, and compliance," said Michael Guastella, vice president of marketing and product development for Cardinal Health's Nuclear Pharmacy Services business. "As we continue to provide our cardiologist customers with access to new radiopharmaceuticals, improved productivity solutions, and better ways to provide high quality, cost-effective patient care, we will continue to utilize opportunities like MedAxiom's Corporate Partner program to innovate across our product and service portfolio."  Cardinal Health, Inc. is a $91 billion, global company serving the health care industry with products and services that help hospitals, physician offices and pharmacies reduce costs, improve safety, productivity and pro
'/>"/>

SOURCE MedAxiom
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Xanodyne Announces Planned President & CEO Succession
2. Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc.
3. Xanodyne Announces Renewed Focus on Pain Management Market
4. Xanodyne Expands U.S. Sales Force and Launches Zipsor(TM) (diclofenac potassium) Liquid Filled Capsules
5. Xanodyne Raises $50 Million in Equity Financing to Support Emerging Product Portfolio
6. Three in Ten Americans Would Use Their Cell Phone to Track Personal Health, Finds PricewaterhouseCoopers
7. Amicus CEO Represents BIO on Rare Diseases at U.S. Senate Committee on Health, Education, Labor and Pensions Bipartisan Hearing
8. FDA Places Politics Above Science, Womens Health, and Informed Consent
9. Seventh Annual Healthcare Unbound Conference Features Innovative Applications of Remote Monitoring, Home Telehealth, mHealth, Social Media and eHealth to Manage Diseases and Promote Wellness
10. North Carolina GlaxoSmithKline Foundation Working With Nonprofits to Promote Health, Science and Education Through Ribbon of Hope Grants
11. Caliper Life Sciences and Stanford University File a Patent Infringement Lawsuit Against Carestream Health, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless continuous ... Doman , Executive Chairman and Interim CEO of Echo ... Tenth Annual Equity Conference. Mr. Doman ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... Calif., May 5, 2011 Rigel Pharmaceuticals, Inc. (Nasdaq: ... chief financial officer, is scheduled to present a company overview ... in Las Vegas on Tuesday, May 10th at 10:00 a.m. ... The presentation will be webcast live and can be accessed ...
... May 5, 2011 Rochester Medical Corporation (NASDAQ: ... ended March 31, 2011. The Company reported record ... for the second quarter of last year.  It also reported ... to net loss of ($351,000) or ($0.03) per diluted share ...
Cached Medicine Technology:Rochester Medical Reports Second Quarter Results 2Rochester Medical Reports Second Quarter Results 3Rochester Medical Reports Second Quarter Results 4Rochester Medical Reports Second Quarter Results 5Rochester Medical Reports Second Quarter Results 6Rochester Medical Reports Second Quarter Results 7Rochester Medical Reports Second Quarter Results 8Rochester Medical Reports Second Quarter Results 9Rochester Medical Reports Second Quarter Results 10
(Date:4/17/2014)... lost its status as the leading weapon against the ... life, with new research indicating it simply needs to ... use of the cheap anti-malarial drug chloroquine in treating ... of more than half a million people each year ... has developed resistance to chloroquine, but research carried out ...
(Date:4/16/2014)... the embryo. It begins as a glob of identical cells ... the cells of our lungs, muscles, nerves and all the ... feat of reverse tissue engineering, Stanford University researchers have begun ... to proliferate and transform into all of the specialized cells ...
(Date:4/16/2014)... 16, 2014): Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced ... of CDX-1401 in solid tumors, including long-term patient follow-up, ... (Vol 6 Issue 232). The data demonstrate robust antibody ... in patients with very advanced cancers and suggest that ...
(Date:4/16/2014)... April 16, 2014 According to a new ... average-risk patients with one to two small polyps are ... cases. This may be an appropriate target for quality ... to quantify adherence to guidelines for timing of repeat ...
(Date:4/15/2014)... , Cases of diabetes and pre-diabetes in the United States ... Johns Hopkins Bloomberg School of Public Health, with obesity apparently ... the burden of the disease has not hit all groups ... the elderly. , According to new research reported in the ...
Breaking Medicine News(10 mins):Health News:Scientists find new way to fight malaria drug resistance 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 3Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2
... , ... ... ... ...
... ... ... , ... , , ...
... of the blood or hematopoietic system derive from stem cell ... to all the different kinds of blood cells equally, said ... a report that appears in the current issue of the ... "While previous reports in journals have hinted at ...
... preparation (ICCBco) in the treatment of lung lesions ... experimental animal model, a research group in China ... pathological changes and pathological effect mechanism of expression ... of portal hypertensive rabbits with schistosomiasis. ...
... In tests, novel immunotherapy appears to combat mesothelioma tumors ... vaccine for the asbestos-related cancer mesothelioma is safe, according ... tested the vaccine -- which infuses a patient,s own ... on 10 patients and found that it induced an ...
... , ... ... ... , ...
Cached Medicine News:Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 2Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 3Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 4Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 5Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 2Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 3Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 4Health News:Theory of single stem cell for blood components challenged 2Health News:Treatment of portal hypertensive pulmonary lesions induced by schistosomiasis 2Health News:Vaccine for Asbestos-Related Cancer Looks Safe 2Health News:Hill-Rom Announces Second Quarter 2010 Dividend 2
... The PalmScan A2000 A-Scan [i.e., PalmScan A2000] ... biometer, which incorporates A-mode pulsed-echo ultrasound,technology, and ... the axial length (AL), anterior,chamber depth (ACD), ... This PalmScan A2000,device is also intended for ...
... TOX/See™ is a 1-step, hand-held, point-of-care device for ... in human urine. The TOX/See device can ... abused drugs in 3 to 8 minutes and ... TOX/See cassette is individually packaged to maximize convenience ...
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
Medicine Products: